<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>MedWorm Tags: bayer healthcare</title>
        <description>MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'bayer healthcare'.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=%22bayer+healthcare%22&t=%22bayer+healthcare%22&r=Exact&o=d&f=tag]]></link>
        <lastBuildDate>Sat, 03 Sep 2011 02:53:16 +0100</lastBuildDate>
        <item>
            <title>Bayer Healthcare UK &quot;Discredited UK Pharma Industry&quot;</title>
            <link>http://www.medworm.com/index.php?rid=5159792&amp;cid=t_180347_147_f&amp;fid=39273&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FePharmaSummit%2F%7E3%2FD72_FKYrmDU%2Fbayer-healthcare-uk-discredited-uk.html</link>
            <description>The continuing saga of Bayer Healthcare's tweets continues to be a news story in the UK drug industry. &amp;nbsp;Last year, Bayer copied two press release headlines, then released them to the public as tweets. &amp;nbsp;In coordination with the Prescription Medicines Code of Practice Authority (PMCPA), Bayer Healthcare UK has violated their Association of the British Pharmaceutical Industry Code of Conduct (ABPI Code). &amp;nbsp;This has resulted in discrediting the Pharma industry in the UK according to the governing board. 

According to The Register, they have discreded the industry by violating these rules:

- Companies are prohibits to release information about prescription-only medicines that would encourage the public to ask their doctor for the product- Bayer Healthcare Failed to maintain high...</description>
            <author>ePharma Summit</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5159792</comments>
            <pubDate>Wed, 24 Aug 2011 14:20:00 +0100</pubDate>
            <guid isPermaLink="false">5159792</guid>        </item>
        <item>
            <title>Bayer Is Scolded For Tweeting Medicines</title>
            <link>http://www.medworm.com/index.php?rid=5008665&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FzOBgzIe-isc%2F</link>
            <description>To Tweet or not to Tweet? That is a question that Bayer Healthcare will be pondering for some time. The drugmaker was upbraided by the UK&amp;#8217;s Prescription Medicines Code of Practice Authority for recently Tweeting about two medicines, which was deemed to be a cause for concern since the information went directly to the public.
What were the Tweets about? In April, the @BayerUKIreland Twitter account wrote this concerning Levitra: “First &amp;#038; only melt-in-the-mouth erectile dysfunction treatment launched by Bayer today http://tinyurl.com/6hfxymf.&amp;#8221; And last year, Bayer tweeted: “Sativex® launched in UK for the treatment of spasticity due to Multiple Sclerosis http://tiny.cc/kiz2y,” according to InPharm.
The voluntary PMCPA industry code that allows a drugmaker to Tweet abo...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=5008665</comments>
            <pubDate>Thu, 07 Jul 2011 12:55:19 +0100</pubDate>
            <guid isPermaLink="false">5008665</guid>        </item>
        <item>
            <title>Bayer Off-Label Promotion Of Yasmin Birth Control Pill For Acne Caused Teenager’s Death: Lawsuit</title>
            <link>http://www.medworm.com/index.php?rid=4945193&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FWTPjB2gXSJE%2F</link>
            <description>The thousands of lawsuits filed against Bayer over alleged injuries and deaths relating to the Yaz and Yasmin contraceptives typically dwell on higher risks beyond those of traditional birth control pills and overly aggressively promotion that failed to disclose the possibility of blood clots, in particular. Now, though, a lawsuit charges off-label promotion for acne caused the death of a 15-year-old girl.
Here&amp;#8217;s the back story&amp;#8230; In 2007, Brittany Prewitt began to develope the skin condition and was prescribed Yasmin, which was never approved for acne, but had allegedly been promoted, nonetheless, to dermatologists. She was not sexually active and the pill was not prescribed, in her case, for contraception, according to her lawsuit, which was filed in a North Carolina state cour...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4945193</comments>
            <pubDate>Sat, 18 Jun 2011 17:04:58 +0100</pubDate>
            <guid isPermaLink="false">4945193</guid>        </item>
        <item>
            <title>The Bayer Discrimination Lawsuit &amp; A Sliding Donut</title>
            <link>http://www.medworm.com/index.php?rid=4872480&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F4QhGY2Ul8hM%2F</link>
            <description>A class action law suit alleging that Bayer HealthCare Pharmaceuticals discriminated against female employees has now been expanded to include female sales reps and all women in the Bayer HealthCare Consumer Care unit, two groups of employees who were not originally part of a discrimination complaint filed two months ago 
The initial lawsuit, filed by six current and former Bayer employees, charges a pattern of discrimination in pay, promotions, and the treatment of pregnant women and mothers. An amended complaint filed yesterday says sales reps were paid less but not promoted as often as men in similar jobs, while women in consumer care were sexually harassed by execs but the drugmaker ignored the problem.
Such charges have emerged in many workplaces, but recently allegations of sex discr...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4872480</comments>
            <pubDate>Thu, 26 May 2011 12:40:48 +0100</pubDate>
            <guid isPermaLink="false">4872480</guid>        </item>
        <item>
            <title>Bayer Bites Lilly Over Animal Health Promotion</title>
            <link>http://www.medworm.com/index.php?rid=4795054&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F7XNwRvu223Y%2F</link>
            <description>When it comes to the animal health business, the laws of the jungle are what matters. Consider the spat between Bayer and Eli Lilly. Over the past year, Lilly&amp;#8217;s Elanco animal health unit allegedly used a smear campaign to discredit Bayer in hopes of convincing veterinarians and distributors to end their business relationships with its rival, according to a lawsuit filed in a New York federal court.
Such fingerpointing complaints are, of course, not an uncommon event among drugmakers, especially when it comes to promotional activities. But this latest lawsuit underscores the extent to which the animal health world is an increasingly important business to companies that are finding it harder and harder to develop big-selling meds to treat those two legged-creatures known as humans.
At ...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4795054</comments>
            <pubDate>Fri, 06 May 2011 20:23:48 +0100</pubDate>
            <guid isPermaLink="false">4795054</guid>        </item>
        <item>
            <title>Speaking on a Big Stage</title>
            <link>http://www.medworm.com/index.php?rid=4122104&amp;cid=t_180347_167_f&amp;fid=38271&amp;url=http%3A%2F%2Frebeccascritchfield.wordpress.com%2F2010%2F10%2F31%2Fspeaking-on-a-big-stage%2F</link>
            <description>Yes, it&amp;#8217;s true. Public speaking is feared more than death. Now, for me, I come alive on a stage. But don&amp;#8217;t get me wrong. I&amp;#8217;m really nervous and want to puke up until I hear the &amp;#8220;Please welcome&amp;#8230;&amp;#8221;
In two weeks, my speaking partner and I, Bernie Salazar (NBC&amp;#8217;s Biggest Loser Season 5 at-home winner) will be headed to New Orleans for some shrimp po&amp;#8217; boys and a major talk with families living with hemophilia.

See Us @ &amp;#8220;Living Fit&amp;#8221; Summit November 12, 2010 New Orleans 


Sponsored By: 



Thanks to Bayer for bringing the Nurture Principles message to families attending the National Hemophilia Foundation&amp;#8217;s Annual Meeting.
Check out the postcards Bernie will be signing at the booth!

&amp;nbsp;
We&amp;#8217;re also doing food demos and exer...</description>
            <author>Balanced Health and Nutrition Rebecca Scritchfield's Blog</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=4122104</comments>
            <pubDate>Sun, 31 Oct 2010 04:39:22 +0100</pubDate>
            <guid isPermaLink="false">4122104</guid>        </item>
        <item>
            <title>Pharmalot… Pharmalittle… Good Morning</title>
            <link>http://www.medworm.com/index.php?rid=3494552&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fg_FWGGerMDQ%2F</link>
            <description>Top of the morning to you. Another shiny day here on the Pharmalot corporate campus, where we ready ourselves for still more meetings and deadlines. You, too? What a coincidence. To prepare, we have gathered a few interesting items to help you along. Meanwhile, we will brew another cup of stimulation. Have a great day, everyone. 
FDA Approves Novartis Organ Rejection Drug (Associated Press)
Amgen Profit Rises On Sales, Price Increases (Bloomberg News)
Genzyme To Pay $175M Consent Decree (Reuters)
Bayer Healthcare Hires Former Novartis Exec (Bloomberg News) (Source: Pharmalot)</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3494552</comments>
            <pubDate>Thu, 22 Apr 2010 12:08:42 +0100</pubDate>
            <guid isPermaLink="false">3494552</guid>        </item>
        <item>
            <title>Mississippi Can Sue Bayer For Medicaid Fraud</title>
            <link>http://www.medworm.com/index.php?rid=3487370&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FLftZiYmSksc%2F</link>
            <description>The Mississippi Supreme Court has revived a lawsuit against Bayer, ruling the state can refile a claim the drugmaker defrauded its Medicaid program, Legal Newsline writes. Bayer Corp. USA was accused of inflating the average wholesale price of meds, causing the state to overpay and the false price reports led the state Medicaid program to spend millions of taxpayers&amp;#8217; dollars unnecessarily.
In 2005, Mississippi Attorney General Jim Hood filed a suit against more than 86 drugmakers, including three Bayer units, accusing them of defrauding the state by inflating average wholesale prices. Bayer argued that under a 2001 settlement with Mississippi over drug pricing, the state had no grounds to sue.
The 2001 settlement, in which Bayer agreed to pay the state $48,608, included a provision t...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3487370</comments>
            <pubDate>Tue, 20 Apr 2010 12:08:08 +0100</pubDate>
            <guid isPermaLink="false">3487370</guid>        </item>
        <item>
            <title>Bayer Pays $97.5M To Settle Kickback Charges</title>
            <link>http://www.medworm.com/index.php?rid=1991560&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F465467996%2F</link>
            <description>The drugmaker reached a settlement with the US Department of Justice, which alleged Bayer paid kickbacks to diabetic suppliers, prompting them to submit false claims to Medicare. The feds claimed Bayer engaged in a &amp;#8216;cash-for-patient&amp;#8217; scheme by paying 11 diabetic suppliers to convert their patients to Bayer products from products - such as glucose monitors and testing strips - made by competitors.
According to the Justice Department Bayer allegedly paid Liberty Medical Supply, one of the largest direct-to-patient suppliers, approximately $2.5 million to convert patients to Bayer supplies. The alleged kickbacks were based on the number of patients that Liberty successfully converted to Bayer products and were disguised as payments for advertising. In addition, Bayer allegedly pai...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1991560</comments>
            <pubDate>Wed, 26 Nov 2008 03:10:39 +0100</pubDate>
            <guid isPermaLink="false">1991560</guid>        </item>
        <item>
            <title>FDA Warns Bayer About Aspirin Marketing</title>
            <link>http://www.medworm.com/index.php?rid=1918199&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F434839486%2F</link>
            <description>The agency sent a pair of warning letters to Bayer HealthCare concerning what it calls two &amp;#8220;unlawful,&amp;#8221; over-the-counter aspirin products — Bayer Women&amp;#8217;s Low Dose Aspirin + Calcium (Bayer Women&amp;#8217;s) and Bayer Aspirin with Heart Advantage (Bayer Heart Advantage). Here is letter one and letter two.
The products, which contain aspirin with either phytosterols or calcium, are unapproved new drugs that require an approved new drug application in order to be legally marketed, according to an FDA statement. In addition to being labeled for use as a pain reliever, both products are labeled for use in reducing the risks of heart disease. Bayer Women&amp;#8217;s is also labeled for use in &amp;#8220;fighting&amp;#8221; osteoporosis. 
However, the FDA says that &amp;#8220;neither product has b...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1918199</comments>
            <pubDate>Tue, 28 Oct 2008 15:56:20 +0100</pubDate>
            <guid isPermaLink="false">1918199</guid>        </item>
        <item>
            <title>Congress Probes Bayer Ads &amp; FDA Web Site</title>
            <link>http://www.medworm.com/index.php?rid=1880157&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F420811435%2F</link>
            <description>As part of its ongoing investigation into direct-to-consumer advertising, the House Energy &amp;#038; Commerce Committee is exploring two new lines of inquiry - why Bayer ignored FDA recommendations to refrain from marketing a version of its aspirin that is also a dietary supplement, and why the FDA hired a public relations firm that works for pharma to develop a consumer web site.
The committee wants to know why Bayer promoted its Bayer Aspirin with Heart Advantage as safe and effective, when the FDA had warned against marketing such a combo. The tablet combines aspirin with a supplement Bayer claims can lower cholesterol. The FDA, however, only regulates the drug.
In a letter to Bayer Healthcare prez Gary Balkema, committee chairman John Dingell and Bart Stupak, who heads the Oversight and I...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1880157</comments>
            <pubDate>Tue, 14 Oct 2008 19:05:52 +0100</pubDate>
            <guid isPermaLink="false">1880157</guid>        </item>
        <item>
            <title>iSense and Their “Glycemic Signature”</title>
            <link>http://www.medworm.com/index.php?rid=1876041&amp;cid=t_180347_134_f&amp;fid=34841&amp;url=http%3A%2F%2Fwww.diabetesmine.com%2F2008%2F10%2Fisense-and-their-glycemic-signature.html</link>
            <description>iPod, iPhone, iPump, iPort, iV-drip (?)&amp;#8230; so no reason to look surprised when you hear about another futuristic diabetes technology company by the name of iSense.
This one, a privately held company based in Oregon, has been working on developing a &amp;#8220;minimally invasive&amp;#8221; continuous glucose monitoring system (CGMS) for about ten years.  (I’m guessing the company [...] (Source: Diabetes Mine)</description>
            <author>Diabetes Mine</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1876041</comments>
            <pubDate>Mon, 06 Oct 2008 11:15:45 +0100</pubDate>
            <guid isPermaLink="false">1876041</guid>        </item>
        <item>
            <title>Europe Launches $3B Drug-Discovery Scheme</title>
            <link>http://www.medworm.com/index.php?rid=1409903&amp;cid=t_180347_150_f&amp;fid=35777&amp;url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F280899326%2F</link>
            <description>New Jersey may be the nation&amp;#8217;s medicine chest, but that&amp;#8217;s nothing compared with being the pharmacy of the world. But where is that pharmacy located? Right now, many would argue it&amp;#8217;s the US. But the European Commission and members of the European Federation of Pharmaceutical Industries and Associations today are releasing details of plan to end Europe&amp;#8217;s declining international role in medical research, Reuters reports.
To be called the Innovative Medicines Initiative, the effort will offers grants to academic institutes and small companies to research ways of beating bottlenecks in the drug development process. Teams of commercial and not-for-profit researchers will be able to seek support on condition that their findings are publicly shared in an effort to stimulate...</description>
            <author>Pharmalot</author>
            <type>blogs</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1409903</comments>
            <pubDate>Wed, 30 Apr 2008 16:43:39 +0100</pubDate>
            <guid isPermaLink="false">1409903</guid>        </item>
    </channel>
</rss>

